Literature DB >> 26732826

Xenograft of human umbilical mesenchymal stem cells from Wharton's jelly as a potential therapy for rat pilocarpine-induced epilepsy.

Pei-Yu Huang1, Yang-Hsin Shih2, Yi-Jhan Tseng3, Tsui-Ling Ko4, Yu-Show Fu5, Yung-Yang Lin6.   

Abstract

We evaluated the effects of intra-hippocampal transplantation of human umbilical mesenchymal stem cells (HUMSCs) on pilocarpine-treated rats. Sprague-Dawley rats were divided into the following three groups: (1) a normal group of rats receiving only PBS, (2) a status epilepticus (SE) group of rats with pilocarpine-induced SE and PBS injected into the hippocampi, and (3) a SE+HUMSC group of SE rats with HUMSC transplantation. Spontaneous recurrent motor seizures (SRMS) were monitored using simultaneous video and electroencephalographic recordings at two to four weeks after SE induction. The results showed that the number of SRMS within two to four weeks after SE was significantly decreased in SE+HUMSCs rats compared with SE rats. All of the rats were sacrificed on Day 29 after SE. Hippocampal morphology and volume were evaluated using Nissl staining and magnetic resonance imaging. The results showed that the volume of the dorsal hippocampus was smaller in SE rats compared with normal and SE+HUMSCs rats. The pyramidal neuron loss in CA1 and CA3 regions was more severe in the SE rats than in normal and SE+HUMSCs rats. No significant differences were found in the hippocampal neuronal loss or in the number of dentate GABAergic neurons between normal and SE+HUMSCs rats. Compared with the SE rats, the SE+HUMSCs rats exhibited a suppression of astrocyte activity and aberrant mossy fiber sprouting. Implanted HUMSCs survived in the hippocampus and released cytokines, including FGF-6, amphiregulin, glucocorticoid-induced tumor necrosis factors receptor (GITR), MIP-3β, and osteoprotegerin. In an in vitro study, exposure of cortical neurons to glutamate showed a significant decrease in cell viability, which was preventable by co-culturing with HUMSCs. Above all, the expression of human osteoprotegerin and amphiregulin were significantly increased in the media of the co-culture of neurons and HUMSCs. Our results demonstrate the therapeutic benefits of HUMSC transplantation for the development of epilepsy, which are likely due to the ability of the cells to produce neuroprotective and anti-inflammatory cytokines. Thus, HUMSC transplantation may be an effective therapy in the future.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Human umbilical mesenchymal stem cells; Pilocarpine; Status epilepticus; Temporal lobe epilepsy; Wharton’s jelly

Mesh:

Substances:

Year:  2015        PMID: 26732826     DOI: 10.1016/j.bbi.2015.12.021

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  14 in total

1.  Mesenchymal Stem Cells Therapy Improved the Streptozotocin-Induced Behavioral and Hippocampal Impairment in Rats.

Authors:  María F Zappa Villar; Juliette López Hanotte; Joaquín Pardo; Gustavo R Morel; Guillermo Mazzolini; Mariana G García; Paula C Reggiani
Journal:  Mol Neurobiol       Date:  2019-08-10       Impact factor: 5.590

2.  Ameliorating Effect of Umbilical Cord Mesenchymal Stem Cells in a Human Induced Pluripotent Stem Cell Model of Dravet Syndrome.

Authors:  Huifang Zhao; Shuai Li; Lang He; Feng Tang; Xiaobo Han; Weiyue Deng; Zuoxian Lin; Rongqi Huang; Zhiyuan Li
Journal:  Mol Neurobiol       Date:  2021-11-11       Impact factor: 5.590

3.  Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton's jelly.

Authors:  Kuo-An Chu; Chang-Ching Yeh; Fu-Hsien Kuo; Wen-Ren Lin; Chien-Wei Hsu; Tien-Hua Chen; Yu-Show Fu
Journal:  Stem Cell Res Ther       Date:  2020-11-30       Impact factor: 6.832

4.  Comparison of mesenchymal stromal cells from peritoneal dialysis effluent with those from umbilical cords: characteristics and therapeutic effects on chronic peritoneal dialysis in uremic rats.

Authors:  Yangchun Du; Ming Zong; Qiunong Guan; Zhongli Huang; Lan Zhou; Jing Cai; Gerald da Roza; Hao Wang; Hualin Qi; Yiping Lu; Caigan Du
Journal:  Stem Cell Res Ther       Date:  2021-07-13       Impact factor: 6.832

5.  Autophagy is required for human umbilical cord mesenchymal stem cells to improve spatial working memory in APP/PS1 transgenic mouse model.

Authors:  Wen Li; Kai Li; Jing Gao; Zhuo Yang
Journal:  Stem Cell Res Ther       Date:  2018-01-15       Impact factor: 6.832

6.  Human Wharton's jelly mesenchymal stem cells protect axotomized rat retinal ganglion cells via secretion of anti-inflammatory and neurotrophic factors.

Authors:  Jose E Millán-Rivero; Francisco M Nadal-Nicolás; David García-Bernal; Paloma Sobrado-Calvo; Miguel Blanquer; Jose M Moraleda; Manuel Vidal-Sanz; Marta Agudo-Barriuso
Journal:  Sci Rep       Date:  2018-11-02       Impact factor: 4.379

7.  Neuroprotective Action of Human Wharton's Jelly-Derived Mesenchymal Stromal Cell Transplants in a Rodent Model of Stroke.

Authors:  Kuo-Jen Wu; Seong-Jin Yu; Chia-Wen Chiang; Yu-Wei Lee; B Linju Yen; Pei-Chi Tseng; Chun-Sen Hsu; Li-Wei Kuo; Yun Wang
Journal:  Cell Transplant       Date:  2018-10-04       Impact factor: 4.064

Review 8.  Wharton' jelly mesenchymal stromal cell therapy for ischemic brain injury.

Authors:  Kuo-Jen Wu; Seong-Jin Yu; Chia-Wen Chiang; Yu-Wei Lee; B Linju Yen; Chun-Sen Hsu; Li-Wei Kuo; Yun Wang
Journal:  Brain Circ       Date:  2018-10-09

9.  Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Wharton's jelly.

Authors:  Kuo-An Chu; Shih-Yao Wang; Chang-Ching Yeh; Tz-Win Fu; Yu-Yi Fu; Tsui-Ling Ko; Mei-Miao Chiu; Tien-Hua Chen; Pei-Jiun Tsai; Yu-Show Fu
Journal:  Theranostics       Date:  2019-09-17       Impact factor: 11.556

10.  Xenografting of human umbilical mesenchymal stem cells from Wharton's jelly ameliorates mouse spinocerebellar ataxia type 1.

Authors:  Pei-Jiun Tsai; Chang-Ching Yeh; Wan-Jhen Huang; Ming-Yuan Min; Tzu-Hao Huang; Tsui-Ling Ko; Pei-Yu Huang; Tien-Hua Chen; Sanford P C Hsu; Bing-Wen Soong; Yu-Show Fu
Journal:  Transl Neurodegener       Date:  2019-09-05       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.